CKD Bio to invest W28.5b in facilities
[DISCLOSURE] Chongkundang Bio (063160) said on Sept. 14 that it has decided to invest 28.5 billion won (US$25.48 million) in new facilities for probiotics to increase manufacturing capacity and to build fill and finish facilities. It will also build microbiome facilities.
This amounts to 20.04 percent of its equity capital and the investment period is until Nov. 30, 2019.
By Hwang You-mee (firstname.lastname@example.org)